MYCN Amplification, Possible Therapies, and BET Bromodomain Inhibition
A new post on the NB Globe website provides a detailed look at MYCN amplification in neuroblastoma, possible therapeutics, and the emergence of a new therapy called BET bromodomain inhibition. “Working with Dana-Farber’s James Bradner, MD, Stegmaier found that the BET bromodomain inhibitor reduced the levels of MYCN protein in lab-grown neuroblastoma cells, resulting in impaired cell growth and induction of cell death. In studies of mice with MYCN-amplified neuroblastoma — including animals with a form of the disease that doesn’t respond to many standard therapies — the drug had anti-tumor effects and prolonged survival” (Source: Science Daily).
Research on BET bromodomain inhibition in neuroblastoma was released in February 2013 and the findings caused a great deal of excitement. The research was also recently presented at the annual meeting of the American Association for Cancer Research (AACR) in Washington (April 6-10, 2013).